Alexion Pharmaceuticals

Insider buying can be an encouraging signal for potential investors. Some insiders were picking up shares in the wake of recent quarterly results. A REIT, a regional bank and a Chinese internet provider saw notable insider purchases reported in the past week Conventional wisdom says...

Short interest in a number of biotech stocks dwindled in the most recent settlement period. However, two stocks bucked that trend in the first two weeks of July. During the period, the share price of one grew and of the other dropped sharply. Biotechnology is one of those segments that...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...

Short interest moves in leading biotech stocks were mixed in the most recent period. However, Illumina, Inc. (NASDAQ: ILMN) and Baxalta Inc (NYSE: BXLT) saw sharp increases in their short interest in late November. Short sellers appeared to lose interest in Juno Lighting LLC (NASDAQ: JUNO) late in...

By and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the July 15 and July 31 settlement dates. The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Celgene Corporation (NASDAQ: CELG), which saw sharp...

By and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the June 15 and June 30 settlement dates. The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Gilead Sciences, Inc. (NASDAQ: GILD), which saw...

Cowen analysts recently released a research report that focused on biotech stocks with promising Phase 3 data leading into the U.S. Food and Drug Administration (FDA) approval process. ACADIA Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), InterMune (NASDAQ: ITMN) and...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...